Thomas Hope
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Thomas Hope sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Thomas Hope: 13 sponsored US clinical trials, 5 recruiting.
Thomas Hope sponsors 13 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 7 completed. 3 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Very High Risk Prostate Carcinoma, with 1 trials.
Top-decile sponsor footprint
Thomas Hope ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
13 total, page 1 of 1
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
NCT06961084
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
NCT07054346
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
NCT06474533
18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas
NCT04895631
Imaging of Solid Tumors Using FAP-2286
NCT04621435
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
NCT04716725
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
NCT05180162
Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms
NCT04044937
Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients
NCT03803475
Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence
NCT03353740
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
NCT03197012
18F-Fluorocholine for the Detection of Parathyroid Adenomas
NCT03764007
Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients
NCT02611882
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 5 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the Thomas Hope pipeline
5 recruiting of 13 indexed (38% open); 7 completed (54%).
Phase mix: 3 late (III/IV) vs 9 early (I/II) (early-phase heavy).
Top condition: Very High Risk Prostate Carcinoma (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Thomas Hope: open-pipeline peers nationwide
Peers matched on 13 registered trials and 38% open enrollment, not the therapeutic-area sidebar.
Thomas Hope sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 trials (± recruiting share)
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors near 38% open enrollment (± trial volume)
- Morehouse School of Medicine · 38% recruiting · 13 trials
- Northeastern University · 38% recruiting · 39 trials
- William Stoops · 38% recruiting · 13 trials
- Xenon Pharmaceuticals · 38% recruiting · 13 trials
Related
What to do with this Thomas Hope page
13 registered trials is a research-attention snapshot, not an endorsement of Thomas Hope or any single study.
- 5 of Thomas Hope's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Very High Risk Prostate Carcinoma is the condition Thomas Hope studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Very High Risk Prostate Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Thomas Hope pipeline card: 13 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.